Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634377 | 0.93 | NQO1 (0.61) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| SCHEMBL3095609 | 0.91 | LTA4H (0.67) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| 1,4-Diethoxybenzene SCHEMBL124015 | 0.84 | NQO1 (1.00) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| 1,4-Diethoxybenzene SCHEMBL28186701 | 0.84 | NQO1 (1.00) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| SCHEMBL4834852 | 0.82 | NQO1 (0.52) | NQO1TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14664976 | 0.81 | NQO1 (0.64) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| SCHEMBL3707799 | 0.81 | LTA4H (0.53) | NQO1LTA4HALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL1018667 | 0.81 | LTA4H (0.55) | TSHRLTA4HSMN1; SMN2CA12CA1 | |
| 1,4-Diethoxybenzene SCHEMBL11794798 | 0.81 | NQO1 (0.93) | NQO1TSHRTDP1LTA4HALDH1A1 | |
| 1,4-Diethoxybenzene SCHEMBL27616183 | 0.78 | NQO1 (0.88) | NQO1TSHRTDP1LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102327-A1 | METHODS FOR COVALENTLY FUNCTIONALIZING SEMICONDUCTING SINGLE WALLED CARBON NANOTUBES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113748184-B | Boron-containing cyclic light-emitting compound and color conversion film containing same | 日东电工株式会社 | 2025-04-04 | — | — | CN | disclosed |
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| CN-112384515-B | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118702683-A | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | BASILEA PHARMACEUTICA AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1278742-A1 | CHROMENYLMETHYLPYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | Basilea Pharmaceutica AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083476-A1 | CHROMENYLMETHYL PYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | NQO1 714/4885TSHR 2853/4885TDP1 1311/4885 |
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NQO1 2251/4885TSHR 567/4885TDP1 4134/4885 |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | NQO1 4195/4885TSHR 1639/4885TDP1 4607/4885 |
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | TK1, TPMT, CTSL | NQO1 2249/4885TSHR 1219/4885TDP1 2623/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | NQO1 2208/4885TSHR 361/4885TDP1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.